Database : MEDLINE
Search on : Mediastinal and Neoplasms [Words]
References found : 21323 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2133 go to page                         

  1 / 21323 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29506496
[Au] Autor:Yon DK; Ahn TK; Shin DE; Kim GI; Kim MK
[Ad] Address:Department of Pediatrics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
[Ti] Title:Extragonadal germ cell tumor of the posterior mediastinum in a child complicated with spinal cord compression: a case report.
[So] Source:BMC Pediatr;18(1):97, 2018 Mar 05.
[Is] ISSN:1471-2431
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Germ cell tumors (GCTs) in children are rare neoplasms with diverse pathological findings according to the site and age of presentation. The most common symptoms in children with mediastinal GCTs, which are nonspecific, are dyspnea, chest pain, cough, hemoptysis, vena cava occlusion syndrome, and fatigue/weakness. Because of these nonspecific symptoms, it is difficult to suspect a mediastinal mass. A posterior mediastinal tumor causing spinal cord compression is an important example of an oncologic emergency arising from a neurogenic tumor. CASE PRESENTATION: Children with posterior mediastinum GCTs can be easily mistaken as having a neurogenic tumor because of site of tumor origin. We treated our 7-year-old patient with emergency decompression surgery and high-dose steroid pulse therapy to prevent secondary injury to the spinal cord. Primary injury was a result of spinal cord compression due to the initial manifestation of GCT in the posterior mediastinum. Cisplatin-based chemotherapy was also administered. The patient was followed up regularly for 3 years and is undergoing rehabilitation without any signs of recurrence. CONCLUSIONS: We present an extremely rare case of a child with paraparesis caused by extradural spinal cord compression as the initial manifestation of GCT in the posterior mediastinum. The child was treated with emergency decompression surgery and high-dose pulse steroid therapy to prevent secondary injury to the spinal cord.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1186/s12887-018-1070-6

  2 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516387
[Au] Autor:Paydary K; Seraj SM; Zadeh MZ; Emamzadehfard S; Shamchi SP; Gholami S; Werner TJ; Alavi A
[Ad] Address:Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
[Ti] Title:The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.
[So] Source:Mol Imaging Biol;, 2018 Mar 07.
[Is] ISSN:1860-2002
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The applications of 2-deoxy-2-[ F]fluoro-D-glucose positron emission tomography/X-ray computed tomography (PET/CT) in the management of patients with breast cancer have been extensively studied. According to these studies, PET/CT is not routinely performed for the diagnosis of primary breast cancer, although PET/CT in specific subtypes of breast cancer correlates with histopathologic features of the primary tumor. PET/CT can detect metastases to mediastinal, axial, and internal mammary nodes, but it cannot replace the sentinel node biopsy. In detection of distant metastases, this imaging tool may have a better accuracy in detecting lytic bone metastases compared to bone scintigraphy. Thus, PET/CT is recommended when advanced-stage disease is suspected, and conventional modalities are inconclusive. Also, PET/CT has a high sensitivity and specificity to detect loco-regional recurrence and is recommended in asymptomatic patients with rising tumor markers. Numerous studies support the future role of PET/CT in prediction of response to neoadjuvant chemotherapy (NAC). PET/CT has a higher diagnostic value for prognostic risk stratification in comparison with conventional modalities. With the continuing research on the treatment planning and evaluation of patients with breast cancer, the role of PET/CT can be further extended.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1007/s11307-018-1181-3

  3 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29223272
[Au] Autor:Linnik YA; Hoegemann Savellano D; Phillips JD; Black CC
[Ad] Address:Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Electronic address: yevgeniy.a.linnik@hitchcock.org.
[Ti] Title:A 49-Year-Old Woman With Right Apical Thoracic Mass.
[So] Source:Chest;152(6):e133-e138, 2017 12.
[Is] ISSN:1931-3543
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:A 49-year-old woman with a medical history of essential hypertension presented to the ED with severe pain in the left superior chest and dull aching pain in the upper flank, lasting for the last 2 days.
[Mh] MeSH terms primary: Ganglioneuroma/diagnosis
Mediastinal Neoplasms/diagnosis
Thoracoscopy/methods
[Mh] MeSH terms secundary: Diagnosis, Differential
Female
Ganglioneuroma/surgery
Humans
Magnetic Resonance Imaging
Mediastinal Neoplasms/surgery
Middle Aged
Radiography, Thoracic
Robotic Surgical Procedures/methods
Tomography, X-Ray Computed
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171211
[St] Status:MEDLINE

  4 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27773666
[Au] Autor:Korevaar DA; Crombag LM; Cohen JF; Spijker R; Bossuyt PM; Annema JT
[Ad] Address:Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: d.a.korevaar@amc.uva.nl.
[Ti] Title:Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung cancer: a systematic review and meta-analysis.
[So] Source:Lancet Respir Med;4(12):960-968, 2016 12.
[Is] ISSN:2213-2619
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Guidelines recommend endosonography with fine-needle aspiration for mediastinal nodal staging in non-small-cell lung cancer, but most do not specify whether this should be through endobronchial endoscopy (EBUS), oesophageal endoscopy (EUS), or both. We assessed the added value and diagnostic accuracy of the combined use of EBUS and EUS. METHODS: For this systematic review and random effects meta-analysis, we searched MEDLINE, Embase, BIOSIS Previews, and Web of Science, without language restrictions, for studies published between Jan 1, 2000, and Feb 25, 2016. We included studies that assessed the accuracy of the combined use of EBUS and EUS in detecting mediastinal nodal metastases (N2/N3 disease) in patients with lung cancer. For each included study, we extracted data on the age and sex of participants, inclusion criteria regarding tumour stage on imaging, details of the endoscopic testing protocol, duration of each endoscopic procedure, number of lymph nodes sampled, serious adverse events occurring during the endoscopic procedures, the reference standard, and 2 × 2 tables for EBUS, EUS, and the combined approach. We evaluated the added value (absolute increase in sensitivity and in detection rate) of the combined use of EBUS and EUS in detecting mediastinal nodal metastases over either test alone, and the diagnostic accuracy (sensitivity and negative predictive value) of the combined approach. This study is registered with PROSPERO, number CRD42015019249. FINDINGS: We identified 2567 unique manuscripts by database search, of which 13 studies (including 2395 patients) were included in the analysis. Median prevalence of N2/N3 disease was 34% (range 23-71). On average, addition of EUS to EBUS increased sensitivity by 0·12 (95% CI 0·08-0·18) and addition of EBUS to EUS increased sensitivity by 0·22 (0·16-0·29). Mean sensitivity of the combined approach was 0·86 (0·81-0·90), and the mean negative predictive value was 0·92 (0·89-0·93). The mean negative predictive value was significantly higher in studies with a prevalence of 34% or less (0·93 [95% CI 0·91-0·95]) compared with studies with a prevalence of more than 34% (0·89 [0·85-0·91]; p=0·013). We found no significant differences in mean sensitivity and negative predictive value between studies that did EBUS first or EUS first, or between studies that used an EBUS-scope or a regular echoendoscope to do EUS. INTERPRETATION: The combined use of EBUS and EUS significantly improves sensitivity in detecting mediastinal nodal metastases, reducing the need for surgical staging procedures. FUNDING: No external funding.
[Mh] MeSH terms primary: Bronchoscopy/methods
Carcinoma, Non-Small-Cell Lung/diagnostic imaging
Endosonography/methods
Lung Neoplasms/diagnostic imaging
Lymph Nodes/diagnostic imaging
Mediastinum/diagnostic imaging
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung/pathology
Endoscopic Ultrasound-Guided Fine Needle Aspiration/methods
Esophagus/diagnostic imaging
Female
Humans
Lung Neoplasms/pathology
Lymph Nodes/pathology
Male
Mediastinum/pathology
Middle Aged
Neoplasm Staging
Predictive Value of Tests
Sensitivity and Specificity
[Pt] Publication type:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Entry month:1712
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:161025
[St] Status:MEDLINE

  5 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29465555
[Au] Autor:Sheth HS; Maldonado F; Lentz RJ
[Ad] Address:D. Y. Patil University School of Medicine, Mumbai, India.
[Ti] Title:Two cases of Dieulafoy lesions of the bronchus with novel comorbid associations and endobronchial ablative management.
[So] Source:Medicine (Baltimore);97(8):e9754, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Dieulafoy lesions are aberrantly large submucosal arteries most frequently associated with gastrointestinal hemorrhage. They are rarely identified in the bronchial submucosa and can cause massive hemoptysis. PATIENT CONCERNS: We present three episodes of massive hemoptysis in two patients, the first with comorbid Alagille syndrome including multiple cardiac and pulmonary vascular abnormalities and the second with thyroid cancer metastatic to the mediastinum. DIAGNOSES: All episodes were due to Dieulafoy lesions of the bronchus based on bronchoscopic appearance. INTERVENTIONS: Bronchoscopic ablation using Nd:YAP laser was attempted both patients. OUTCOMES: Nd:YAP laser successfully ablated the Dieulafoy lesion in the first case with long-term relief from recurrent hemoptysis. The first episode in the second patient responded to bronchial artery embolization; laser ablation of a different Dieulafoy lesion responsible for the second episode was unsuccessful but additional bronchial artery embolization has provided relief from further episodes. LESSONS: Bronchoscopic ablation of Dieulafoy lesions of the bronchus can provide durable relief from recurrent symptoms. Clinical and anatomical features should be considered carefully before intervention, which should only be attempted by experienced operators with appropriate ancillary support available.
[Mh] MeSH terms primary: Ablation Techniques/methods
Bronchial Diseases/surgery
Bronchoscopy/methods
Hemoptysis/surgery
Vascular Malformations/surgery
[Mh] MeSH terms secundary: Aged
Alagille Syndrome/pathology
Bronchi/blood supply
Bronchi/surgery
Bronchial Diseases/complications
Comorbidity
Female
Hemoptysis/etiology
Humans
Male
Mediastinal Neoplasms/secondary
Middle Aged
Thyroid Neoplasms/pathology
Vascular Malformations/complications
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009754

  6 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29390285
[Au] Autor:Zhang Y; Xin J; Ma Y; Li Q; Liu B
[Ad] Address:Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
[Ti] Title:Use of Univent tube for intermittent lung isolation during thoracoscopic mediastinal tracheal resection and reconstruction: A case report.
[So] Source:Medicine (Baltimore);96(50):e8945, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Primary tracheal adenoid cystic carcinoma of the trachea primary is a rare neoplasm and commonly misdiagnosed. Lung isolation during surgery and ventilation pose a tremendous challenge to anesthesiologists. PATIENT CONCERNS: The authors describe a novel technique of lung isolation and ventilation with a Univent tube during thoracoscopic mediastinal tracheal resection and reconstruction in a female patient. DIAGNOSES: Primary tracheal adenoid cystic carcinoma, nonsmall cell carcinoma. INTERVENTIONS: In this case, tracheal resection and reconstruction were performed. A bronchial blocker of the Univent tube was used as a guide to manipulate the depth of endotracheal tube. OUTCOMES: The intermittent 1-lung ventilation was established successfully. The patient recovered uneventfully and discharged after 10 days. LESSONS: The advantages of approach include a stable airway management without occupying the contracted space of thoracoscope and no potential risk of trapping or barotraumas.
[Mh] MeSH terms primary: Airway Management/methods
Carcinoma, Adenoid Cystic/surgery
Thoracoscopy
Tracheal Neoplasms/surgery
[Mh] MeSH terms secundary: Carcinoma, Adenoid Cystic/diagnosis
Carcinoma, Adenoid Cystic/pathology
Female
Humans
Intubation, Intratracheal
Middle Aged
Tracheal Neoplasms/diagnosis
Tracheal Neoplasms/pathology
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008945

  7 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29390280
[Au] Autor:Liu Y; Luo D; Du T; Wang H
[Ad] Address:Department of Thoracic Surgery, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, Xinjiang.
[Ti] Title:Clinical and pathology analysis of 1 case of adult pleural pulmonary blastoma: A case report.
[So] Source:Medicine (Baltimore);96(50):e8918, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Pulmonary blastoma is a rare primary lung cancer that can be categorized into adult type and child type. The clinical symptoms and imaging features of pulmonary blastoma are nonspecific, making it difficult to diagnose preoperatively. Postoperative pathology with immunohistochemical staining can help diagnosis. PATIENT CONCERNS: A 53-year-old male had chest tightness and shortness of breath. DIAGNOSES: The patient was diagnosed as pleural pulmonary blastoma based on computed tomography (CT) scan, pathology, immunohistochemistry, and molecular pathology. CT examination showed solid mass on the upper lobe of the left lung Intraoperative observation found that tumor tissue was gray with tough texture. The surrounding lung tissue showed AE1/AE3 (+), Vimentin (+), and CD34 (+) staining. No epidermal growth factor receptor gene mutation was detected. INTERVENTIONS: The left lobe resection plus mediastinal lymph node dissection were performed. After the operation, patient received paclitaxel combined with nedaplatin chemotherapy for 4 times. OUTCOMES: Four months later, left pleural metastasis, and mediastinal lymph node metastasis was found. The patient died 15 months later. LESSONS: Pleural pulmonary blastoma is a malignant tumor with rare pathological features that is easy to relapse and metastasis with poor prognosis. Surgical treatment preferably, lobectomy plus mediastinal lymph node dissection, is the first treatment option. The overall prognosis is poor.
[Mh] MeSH terms primary: Lung Neoplasms/diagnosis
Pulmonary Blastoma/diagnosis
[Mh] MeSH terms secundary: Diagnosis, Differential
Fatal Outcome
Humans
Immunohistochemistry
Lung Neoplasms/pathology
Lung Neoplasms/therapy
Lymph Node Excision
Male
Middle Aged
Pulmonary Blastoma/pathology
Pulmonary Blastoma/therapy
Tomography, X-Ray Computed
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008918

  8 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29390263
[Au] Autor:Cai S; Deng H; Chen Y; Wu X; Guan X
[Ad] Address:Department of Oncology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
[Ti] Title:Treatment of medullary thyroid carcinoma with apatinib: A case report and literature review.
[So] Source:Medicine (Baltimore);96(50):e8704, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Medullary thyroid carcinoma (MTC) is a rare type thyroid carcinoma originating from the thyroid parafollicular cells (C cells). Chemotherapy has a limited efficacy for treating persistent or recurrent MTC. PATIENT CONCERNS: A 46-year-old woman who underwent thyroidectomy for MTC in December 2007. She began experience recurring diarrhea in January 2015 and started to cough and feel shortness of breath in March 2016. DIAGNOSES: A chestcomputed tomography (CT) scan showed metastases in the bilateral lungs, pulmonary hilum, and mediastinal lymph nodes. Percutaneous biopsy of the pulmonary occupying lesions performed on March 21, 2016 indicated medullary carcinoma metastases at the right pulmonary hilum. INTERVENTIONS: This patient was treated with oral apatinib (500 mg daily). OUTCOMES: The patient's symptoms of diarrhea, coughing, and shortness of breath disappeared. CT reexaminations for efficacy assessment at 1, 2, and 3 months after the treatment indicated partial remission. Systemic migrating bone and joint pains occurred during the treatment, which were considered to be adverse events of apatinib. LESSONS: Treatment of MTC with apatinib has been shown to be effective in our case. Tyrosine kinase inhibitors (TKIs) that suppress rearranged during transfection (RET) and vascular endothelial growth factor receptor (VEGFR) should be considered as a effective therapeutic approaches.
[Mh] MeSH terms primary: Carcinoma, Neuroendocrine/drug therapy
Carcinoma, Neuroendocrine/secondary
Lung Neoplasms/drug therapy
Lung Neoplasms/secondary
Protein Kinase Inhibitors/therapeutic use
Pyridines/therapeutic use
Thyroid Neoplasms/pathology
[Mh] MeSH terms secundary: Female
Humans
Middle Aged
Thyroid Neoplasms/therapy
Thyroidectomy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Protein Kinase Inhibitors); 0 (Pyridines); 5S371K6132 (apatinib)
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008704

  9 / 21323 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27770251
[Au] Autor:Tertemiz KC; Alpaydin AO; Karacam V
[Ad] Address:Department of Pulmonary Diseases, Dokuz Eylul University Medical Faculty, 35340, Balcova, Izmir, Turkey. tkemalcan@yahoo.com.
[Ti] Title:The role of endobronchial ultrasonography for mediastinal lymphadenopathy in cases with extrathoracic malignancy.
[So] Source:Surg Endosc;31(7):2829-2836, 2017 Jul.
[Is] ISSN:1432-2218
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Many extrathoracic malignancies can metastasize to lungs and mediastinal lymph nodes. Whether mediastinal lesions are metastasis in these patients changes staging, prognosis, and treatment strategy. In this study, we aimed to find out the contribution of EBUS-TBNA to the diagnosis in cases with extrathoracic malignancy. MATERIALS AND METHODS: Patients who had been previously diagnosed as extrapulmonary solid organ malignancy and in whom mediastinal or hilar lymphadenopathy developed during their follow-up and EBUS-TBNA was applied for diagnostic purposes were retrospectively included in this study. RESULTS: A total of 91 patients consisting of 35 females (38.5 %) and 56 males (61.5 %) were included in the study. The mean age of the patients was 60.5 (±11.4). Malignancy was not observed in 54 (59.3 %) patients; primary malignancy metastasis was detected in 33 (36.3 %) patients, and primary lung cancer was detected in 4 (4.4 %) patients with EBUS-TBNA. The sensitivity of EBUS-TBNA in extrathoracic malignancies was determined as 90.2 %; its specificity was determined as 100 %, its negative predictive value as 92.5 %, its positive predictive value as 100 %, and its diagnostic accuracy as 95.6 %. The highest rate was determined in the left lower paratracheal lymph node when they were examined in terms of malignancy detection rate in lymph node stations. CONCLUSION: EBUS-TBNA is a minimally invasive method with quite a low complication rate that does not require general anesthesia. It should be the first step method to be used in the diagnosis of mediastinal and hilar lymphadenopathies seen in extrathoracic malignancies since it has high diagnostic accuracy, sensitivity, and specificity. EBUS-TBNA significantly reduces the need for surgical intervention. Further surgical interventions can be planned in patients in whom diagnostic competence is not ensured.
[Mh] MeSH terms primary: Bronchoscopy/methods
Endoscopic Ultrasound-Guided Fine Needle Aspiration/methods
Lung Neoplasms/diagnostic imaging
Lung Neoplasms/secondary
Lymph Nodes/diagnostic imaging
Lymphadenopathy/diagnostic imaging
[Mh] MeSH terms secundary: Aged
Diagnosis, Differential
Female
Follow-Up Studies
Humans
Lung Neoplasms/pathology
Lymph Nodes/pathology
Lymphadenopathy/pathology
Lymphatic Metastasis
Male
Mediastinum
Middle Aged
Retrospective Studies
Sensitivity and Specificity
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[Js] Journal subset:IM
[Da] Date of entry for processing:161023
[St] Status:MEDLINE
[do] DOI:10.1007/s00464-016-5293-z

  10 / 21323 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29265182
[Au] Autor:Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xaiver AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
[Ad] Address:Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
[Ti] Title:R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
[So] Source:Br J Haematol;180(4):534-544, 2018 02.
[Is] ISSN:1365-2141
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is an uncommon subtype of non-Hodgkin lymphoma (NHL) that presents with a mediastinal mass and has unique clinicopathological features. Historically, patients with PMBCL were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy ± involved field radiation. Since a phase II trial, published in April 2013, demonstrated excellent results using dose-adjusted (DA) R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), this treatment has gained popularity. We performed a retrospective, multicentre analysis of patients aged ≥18 years with PMBCL since January 2011. Patients were stratified by frontline regimen, R-CHOP versus DA-R-EPOCH. 132 patients were identified from 11 contributing centres (56 R-CHOP and 76 DA-R-EPOCH). The primary outcome was overall survival. Secondary outcomes included progression-free survival, complete response (CR) rate, and rates of treatment-related complications. Demographic characteristics were similar in both groups. DA-R-EPOCH use increased after April 2013 (79% vs. 45%, P < 0·001), and there was less radiation use after DA-R-EPOCH (13% vs. 59%, P < 0·001). While CR rates were higher with DA-R-EPOCH (84% vs. 70%, P = 0·046), these patients were more likely to experience treatment-related toxicities. At 2 years, 89% of R-CHOP patients and 91% of DA-R-EPOCH patients were alive. To our knowledge, this represents the largest series comparing outcomes of R-CHOP to DA-R-EPOCH for PMBCL.
[Mh] MeSH terms primary: Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Lymphoma, B-Cell/drug therapy
Mediastinal Neoplasms/drug therapy
[Mh] MeSH terms secundary: Adult
Aged
Antibodies, Monoclonal, Murine-Derived/adverse effects
Antibodies, Monoclonal, Murine-Derived/therapeutic use
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Combined Modality Therapy
Cyclophosphamide/adverse effects
Cyclophosphamide/therapeutic use
Disease Management
Doxorubicin/adverse effects
Doxorubicin/therapeutic use
Etoposide/adverse effects
Etoposide/therapeutic use
Female
Humans
Lymphoma, B-Cell/diagnosis
Lymphoma, B-Cell/mortality
Male
Mediastinal Neoplasms/diagnosis
Mediastinal Neoplasms/mortality
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prednisone/adverse effects
Prednisone/therapeutic use
Recurrence
Retrospective Studies
Rituximab/administration & dosage
Treatment Failure
Treatment Outcome
Vincristine/adverse effects
Vincristine/therapeutic use
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Name of substance:0 (Antibodies, Monoclonal, Murine-Derived); 0 (R-CHOP protocol); 4F4X42SYQ6 (Rituximab); 5J49Q6B70F (Vincristine); 6PLQ3CP4P3 (Etoposide); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone)
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[Js] Journal subset:IM
[Da] Date of entry for processing:171222
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15051


page 1 of 2133 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information